医脉通导读2025年6月30日，替尔泊肽注射液正式获得中国国家药品监督管理局（NMPA）批准，成为首个且目前唯一一个适用于治疗成人肥胖患者的中重度阻塞性睡眠呼吸暂停（OSA）的处方药。替尔泊肽可改善中度至重度阻塞性睡眠呼吸暂停肥胖成人患者的睡眠障碍。

阻塞性睡眠呼吸暂停是一种常见的睡眠障碍，主要表现为在睡眠过程中反复出现呼吸暂停。这种疾病在30至69岁的人群中尤为普遍，全球估计有4.25亿人患有中度至重度OSA。仅在中国，患者人数就高达1.76亿，形势可谓严峻。OSA不仅影响患者的睡眠质量，还会引发一系列健康问题。研究表明，OSA患者发生中风的概率是普通人的4.33倍，病死率则是普通人的1.98倍。

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

减肥药物生产商诺和诺德 (NVO.US)和礼来 (LLY.US)的股票可能会受益，因为美国心脏病学会 (ACC)建议，肥胖患者在选择预防心脏病的治疗方案时，肥胖症药物应作为主要选项之一。该非营利性医疗协会在周五发布的最新《简明临床指南》中指出，与肥胖相关的心脏疾病 (如高血压)“越来越多地可以通过现代减肥药物来治疗，其风险要低于基于手术的干预措施。” ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

The World Health Organization continues its investigation into the origins of COVID-19, with significant information still needed. Concurrently, Americans like Amy Spencer are crafting their own ...